



**Interim Financial Statements
as at March 31, 2006**

prepared according to International
Financial Reporting Standards (IFRS)

Six-Month Report 2005/2006

Dear Shareholder,

During the first half of its 2005/2006 financial year (1 October 2005 – 31 March 2006) Sanochemia Pharmazeutika AG was able to increase group turnover by 8% to €16.4 million (from €15.2m). This is largely attributable to the segments Diagnostics (imaging agents) and Research and Development (licensing income). The Production segment reported a decline in sales revenues and results, predominantly due to a prepayment for future galantamine deliveries which will be reflected in results over a number of years. Nonetheless, all three operative segments reported positive bottom lines.

During the reporting period the company was able to reach a major milestone following the conclusion of an out-licensing agreement relating to our tolperisone project in North America. This project will not only generate future revenues through licensing and milestone payments, but will also secure additional orders for the Production division (from 2006/2007). We were also able to report securing patent protection covering the process developed by Sanochemia for the synthesis of the active pharmaceutical ingredient (API) tolperisone.

These developments are additional indications that Sanochemia is pushing ahead with its strategy of focusing on specialty pharmaceuticals. The current intensification of R&D activities, the establishment of a robust product pipeline and the profitable expansion of our diagnostics business, all combine to further reduce our dependence on galantamine revenues.

Earnings before interest and tax (EBIT) of €1.7m (€2.2m) and a financial result of €1.0m (€2.0m) lie within the parameters noted in recent periods. The pre-tax result (EBT) of €2.6m (€4.2m) yielded net earnings after tax of €2.0m (€2.9m) equivalent to €0.21 (€0.30) per share. The Board of Management again forecasts a firm positive result at the end of the financial year.

HUMAN PHARMACEUTICALS – Sales up by seven percent while EBIT improves by 50%

Sales revenues of T€6,039 (T€5,665) +7%
EBIT of T€512 (T€341) +50%

The business segment Human Pharmaceuticals (sales of diagnostic products) posted a net increase in sales revenues of seven percent for the first two quarters. As a result of tight cost controlling, EBIT improved markedly to T€512 (from T€341) – further evidence that Sanochemia Diagnostics' turnaround is sustainable.

The seven percent increase in sales revenues fails, however, to adequately reflect our success in the area of exports which, driven by new markets for Scanlux (our top-selling radiological product), increased by 38%. Despite discontinuing several unprofitable products, sales in the German market remained essentially stable while the operating result improved significantly in comparison with the same period a year earlier.

Our US subsidiary, Sanochemia Corporation, will play a more central role in coming periods following the upcoming launch of the x-ray contrast agent Scanlux alongside its existing success with sales of an HIV test. The roll-out of Scanlux in the US, due in 2007/2008, is expected to generate a significant increase in high-margin sales in the world's most important pharmaceutical market. Preparations are proceeding on schedule with a regulatory filing with the FDA forecast before the end of this calendar year.

PRODUCTION – Decline in year-on-year sales and results due to one-off effect of earlier prepayment

Sales revenues of T€7,879 (T€9,487) -17%
EBIT of T€1,979 (T€4,351) -55%

Due to a one-off prepayment of T€8,823 for the production and delivery of galantamine in the previous financial year, a provision for which is being reversed over several years, the Production segment reported sales of T€7,879, or 17% lower than a year earlier (T€9,487), and EBIT of T€1,979 (T€4,351). It is expected that the start of tolperisone production next year will counteract this factor.

R & D – First licensing revenues from tolperisone project

Sales revenues of T€2,452 (T€2)
EBIT of T€1,086 (T€-913)

During the last quarter our R & D division was able to report its first significant revenues, in the amount of T€2,452, following the successful out-licensing of the tolperisone project in North America. The receipt of this amount as an upfront payment played a major role in achieving this segment's positive EBIT of T€1,086 (T€-913). The regulatory work associated with tolperisone in Germany and Switzerland is on schedule, while the patent covering the synthesis process, awarded in the last quarter, provides comprehensive patent protection through 2022.

In March we were able to report on the considerable progress made in the development of our bladder cancer diagnostic based on the substance PVP hypericin. Having successfully manufactured the product on an industrial scale, we soon expect to be able to begin making a further lucrative product at our own facility in Neufeld, Austria.

Research and development expenditure for the year to date stands at €2.9m (€2.0m), which is in line with the budget for the year to September of six million euros.

Sanochemia shares



Sanochemia's shares are listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN AT0000776307). The share price developed positively during the first half and stood at €17.53 at the close of the period (31 March 2006) having opened at €9.85 on 3 October 2005. A series of encouraging announcements including the operational turnaround and the successful out-licensing of our muscle relaxant played their part in boosting the share price. The share performance for the first half was 77.97% - far exceeding that of relevant indices such as the Prime Pharma & Healthcare Performance Index and the TecDAX.

Josef Böckmann, Chief Executive Officer
Herbert Frantsits, Chief Financial Officer
Anton Dallos, Chief Technical Officer
Maximilian Hudl, Chief Marketing Officer

TABLE OF CONTENTS

- Report on the auditor's examination of the interim financial statements at/to 31 March 2006
- Consolidated Profit and Loss Account to 31 March 2006 – prepared according to IFRS
- Consolidated Balance Sheet at 31 March 2006 – prepared according to IFRS
- Consolidated Cashflow Statement to 31 March 2006 – prepared according to IFRS
- Notes to the Consolidated Interim Financial Statements to 31 March 2006 – prepared according to IFRS

REVIEW REPORT
(TRANSLATION)

To the Members of the Management Board and
the Supervisory Board of
Sanochemia Pharmazeutika AG

We have reviewed the accompanying consolidated quarterly financial statements of Sanochemia Pharmazeutika AG as of March 31, 2006. These financial statements are the responsibility of the Company's management. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the International Standard on Review Engagements (ISRE) 2400, "Engagements to Review Financial Statements" as issued by the International Auditing and Assurance Standards Board (IAASB) of the International Federation of Accountants (IFAC). These standards require that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated quarterly financial statements of Sanochemia Pharmazeutika AG as of March 31, 2006 do not give a true and fair view in accordance with International Financial Reporting Standards (IFRSs) as adopted by the EU.

Vienna, May 5, 2006


Mag. Isabella Schwartz-Gallée
(Wirtschaftsprüferin)

 ERNST & YOUNG
WIRTSCHAFTSPRÜFUNGSGESELLSCHAFT MBH


ppa. Mag. Ernst Schönhuber
(Wirtschaftsprüfer)

IFRS Consolidated Profit and Loss Account

	01/2006-03/2006	01/2005-03/2005	10/2005-03/2006	10/2004-03/2005
Note	T€	T€	T€	T€
Sales revenues	(1) 9.196	7.545	16.370	15.163
Other income	(2) 888	1.011	1.640	1.268
Write-back of investment grants	38	41	76	82
Changes in inventory	-972	280	-1.863	181
Own work capitalised	685	444	1.237	951
Operating performance	9.835	9.321	17.460	17.645
Costs of materials and services	-2.022	-2.908	-4.004	-5.173
Personnel expenses	-1.974	-1.868	-4.026	-3.710
Amortisation of intangible assets and depreciation of fixed assets	-993	-991	-1.942	-1.968
Other expenses	-3.538	-2.145	-5.815	-4.563
Operating result	1.308	1.409	1.673	2.231
Interest paid	-114	-136	-239	-283
Interest earned	206	176	375	336
Other financial income/expenses	-249	1.132	770	1.959
Income from financing activities	-157	1.172	906	2.012
Pre-tax profit	1.151	2.581	2.579	4.243
Income taxes	-158	-751	-562	-1.306
Net profit	993	1.830	2.017	2.937
of which minority interests	-57	-25	-103	-93
of which parent company	1.050	1.856	2.120	3.031
Earnings per share in EUR	(3) 0,10	0,18	0,21	0,30
Diluted earnings per share in EUR	0,10	0,18	0,21	0,30
Weighted number of shares issued	10.155.598	10.155.598	10.155.598	10.155.598

IFRS Consolidated Balance Sheet

ASSETS	<i>Note</i>	31.3.06 <u>T€</u>	30.9.05 <u>T€</u>
Leasehold improvements		8.074	7.850
Property, plant and equipment		6.772	7.165
Other equipment, furniture & fixtures		765	839
Property, plant and equipment under construction		<u>803</u>	<u>713</u>
Fixed assets		16.414	16.567
Goodwill		3.418	3.418
Capitalised development costs		8.546	7.309
Other intangible assets		<u>7.187</u>	<u>7.843</u>
Intangible assets		19.151	18.570
Financial investments		2	2
Deferred tax assets		<u>361</u>	<u>683</u>
Non-current assets		<u>35.928</u>	<u>35.822</u>
Inventory		7.519	7.511
Other receivables and assets		5.617	2.694
Accounts receivable - affiliated companies	(4)	0	93
Accounts receivable - trade		8.670	8.925
Receivables from research subsidies	(5)	110	922
Securities	(6)	15.889	16.408
Cash and cash equivalents		<u>23.225</u>	<u>18.656</u>
Current assets		<u>61.030</u>	<u>55.209</u>
 Total ASSETS		 <u>96.958</u>	 <u>91.031</u>

IFRS Consolidated Balance Sheet

LIABILITIES & SHAREHOLDERS' EQUITY	<i>Note</i>	31.3.06 <u>T€</u>	30.9.05 <u>T€</u>
Shareholders' equity less minority interests		59.769	57.779
Shareholders' equity	(7)	60.878	58.784
Share capital		10.156	10.156
Additional paid-in capital		48.761	48.761
Gain/loss available for sale securities		53	7
Foreign currency translations		17	-14
Profit and loss account		1.891	-126
Minority interests		<u>-1.109</u>	<u>-1.005</u>
Bank loans and overdrafts	(8)	16.617	12.867
Employee benefit provisions		680	704
Deferred income	(9)	4.363	5.739
Investment grants from public funds		<u>1.593</u>	<u>1.655</u>
Non-current liabilities		<u>23.253</u>	<u>20.965</u>
Bank loans and overdrafts	(10)	1.974	3.458
Accounts payable - trade		1.956	2.065
Accounts payable - affiliated companies	(11)	297	106
Other liabilities and accruals		6.631	4.548
Deferred income		1.429	792
Deferred tax liabilities		470	243
Other provisions		<u>70</u>	<u>70</u>
Current liabilities		<u>12.827</u>	<u>11.282</u>
Total liabilities and shareholders' equity		<u><u>96.958</u></u>	<u><u>91.031</u></u>

IFRS Consolidated Cash flow Statement

	10/05-03/06 T€	10/04-03/05 T€
Net income before taxes	2.579	2.072
Depreciation of fixed and intangible assets	1.942	2.306
Write-down / write-up of securities	154	4
Gain/loss from the disposal of fixed and intangible assets	37	-8
Interest payments	239	408
Interest receipts	-375	-146
Receipts from securities	-162	-80
Non-realised gains/losses through currency translation	31	5
Reversal of investment grants	-62	-76
Change in inventory	-8	-3.110
Change in receivables and other assets	-2.641	1.309
Change in receivables from research grants	812	-105
Change in accounts payable - including those due to affiliated companies	81	-117
Change in other liabilities including accruals	2.083	388
Change in employee benefit provisions	-24	41
Cash flow from current operating activities	4.686	2.891
Interest payments	-249	-408
Interest receipts	390	146
Receipts from securities	225	80
Income tax payments	-11	10
Cash flow from operating activities	5.041	2.719
Investments in intangible assets	-1.577	-1.107
Investments in fixed assets	-833	-2.096
Purchase of securities	-33.728	-2.348
Receipts from the disposal of fixed assets	0	8
Receipts from the disposal of securities	34.139	2.335
Cash flow from investment activities	-1.999	-3.208
Raising of long-term borrowings	3.750	1.444
Repayment of short-term borrowings	-1.485	-500
Financing from research grants	0	300
Repayment of research promotion loans	-738	-5
Cash flow from financing activities	1.527	1.239
Change in cash and cash equivalents	4.569	750
Cash and cash equivalents		
Balance at beginning of period	18.656	12.190
Change in funds during the period	4.569	750
Influence of exchange rate differences on financial assets	0	5
Balance at end of period (1)	23.225	12.945

(1) The liquid funds include cash and cash in bank

Sanochemia Pharmazeutika AG

Notes to the Interim Financial Statements at 31 March 2006 Prepared according to International Financial Reporting Standards (IFRS)

I. GENERAL INFORMATION

Information on the Company

Sanochemia Pharmazeutika AG, Vienna, and its subsidiaries are engaged in the production and sale of pharmaceuticals and diagnostics for human medicine and the synthetic production of galantamine, an active pharmaceutical ingredient used in a drug to treat Alzheimer's disease.

The consolidated financial statements of Sanochemia Pharmazeutika AG at 31 March 2006 have been prepared in accordance with International Financial Reporting Standards (IFRS) applicable for the 2005/2006 financial year and as intended for use within the EU. The rules of International Accounting Standards (IAS) 34 – Interim Financial Statements – have been applied.

The company's balance sheet date is 30 September.

The consolidated interim financial statements have been prepared consolidating the same subsidiaries as in the previous financial period

The interim financial statements have been prepared in thousand euro (T€), figures indicated in the notes are expressed in thousand euro (T€), unless otherwise stated.

Shares held by Executive Officers

The following shares and authorised options are held by the company's executive officers at 31 March 2006:

	Share holding	Option
Dr. Josef Böckmann	18,750	15,000
Anton Dallos	15,340	15,000
Herbert Frantsits	15,170	15,000
Dr. Werner Frantsits	2,100	0
Eveline Frantsits	1,350	0
Wolfgang Stein	680	0
Dr. Johannes Respondek	0	0
Maximilian Hudl	1,350	0
Dr. Heinrich Unger ¹⁾	500	0
Günter Kahler ¹⁾	500	0

- 1) Dr. Heinrich Unger and Mr. Günter Kahler were elected to the Supervisory Board on the occasion of the last ordinary shareholders' meeting on 9 March 2006.

The exercising of the options by the members of the Board of Management at the issue price (€ 21.50) is subject to the option plan, and therefore only possible if the average share price in the month prior to the Annual Shareholders' Meeting in March rises by at least 15% p.a. (additive) above the issue price. Up to a quarter of each option can be exercised in the month after the Annual Shareholders' Meeting of each financial year until 2007/2008. Since this increase in the share price was not reached in January 2006, these options could not be exercised in 2006.

The share options will be included in the accounts for the first time when the conditions for the exercising of the options are determined to have been met. No inclusion of the share options in the financial statements shall precede this. At 31 March 2006, no inclusion of the share options in the financial statements was required.

Accounting and valuation principles

The interim financial statements have generally been prepared according to the same accounting and valuation principles as applied in the last annual consolidated financial statements.

Fluctuations in the regularity of receipts and expenses with concomitant impact on quarterly results are confined to the area of synthesis production.

II. NOTES TO THE PROFIT AND LOSS ACCOUNT

OPERATING RESULT

(1) SALES REVENUES

Following the completion of an agreement with the US company Avigen Inc. concerning the out-licensing of tolperisone, a one-off milestone payment in the amount of USD 3 million was received.

For more detailed information on sales revenues refer to **SEGMENT REPORTING** under **IV. Other information.**

(2) OTHER OPERATING INCOME

in T€	<u>10/2005-03/2006</u>	<u>10/2004-03/2005</u>
Income from the disposal and write-up of tangible and intangible assets	0	1
Reversal of deferred income	738	9
<i>Forschungsförderungsfond der gewerblichen Wirtschaft</i>	204	83
Personnel costs passed on to third parties	130	161
Income through currency differences	14	6
Other income	554	1,008
Total	<u>1,640</u>	<u>1,268</u>

(3) EARNINGS PER SHARE

Since the option rights were not exercisable, the diluted earnings per share are equal to the earnings per share. The number of shares issued remained unchanged.

The earnings per share (rounded to two decimal places) for the quarters 10/2005 – 03/2006 amount to € 0.21 (10/2004 – 03/2005: € 0.30 per share) arising out of profits in the amount of T€2,120 (10/2004 – 03/2005: T€3,031).

III. NOTES TO THE BALANCE SHEET

Significant balance sheet items are discussed below.

ASSETS

(4) RECEIVABLES DUE FROM AFFILIATED COMPANIES

<u>in T€</u>	<u>31.03.2006</u>	<u>30.09.2005</u>
Medinger GmbH	0	93

(5) RECEIVABLES FROM RESEARCH PROMOTION PROGRAMMES

<u>In T€</u>	<u>31.03.2006</u>	<u>30.09.2005</u>
Forschungsförderungsfonds für die gewerbliche Wirtschaft, Vienna	0	52
Wirtschaftsservice Burgenland AG	180	870
Forschungsförderungsgesellschaft mbH	-70	0
<u>Total</u>	<u>110</u>	<u>922</u>

These receivables relate to research grants which have been awarded and for which a high degree of certainty exists that the preconditions for non-repayment can be met.

(6) MARKETABLE SECURITIES

The securities are made up predominantly of investments in fixed interest rate bonds and investment funds.

The change in the marketable value of the securities held has been fully reflected in the shareholders' equity.

SHAREHOLDERS' EQUITY AND LIABILITIES

(7) SHAREHOLDERS' EQUITY

in T€	Equity Capital	Capital reserves	Gain/loss available for sale securities	Currency translation differences	Net profit/loss for the year	Minority interests	Total
Balance at 30.09.2004	10,156	48,761	2	-3	-5,774	0	53,142
Valuation of securities	0	0	5	0	0	0	5
Currency translation differences	0	0	0	-11	0	0	-11
Gains / losses not recorded in the Profit and Loss Account	0	0	5	-11	0	0	-6
Consolidated net result	0	0	0	0	5,648	0	5,648
Balance at 30.09.2005	10,156	48,761	7	-14	-126	0	58,784
Valuation of securities	0	0	46	0	0	0	46
Currency translation differences	0	0	0	31	0	0	31
Gains / losses not recorded in the Profit and Loss Account	0	0	46	31	0	0	77
Consolidated net result	0	0	0	0	2,017	0	2,017
Balance at 31.03.2006	10,156	48,761	53	17	1,891	0	60,878

As in the previous financial year, on the balance sheet date the share capital consisted of 10,155,598 nonpar shares equivalent to an amount of € 1.00 per share.

At the close of this reporting period (31 March 2006), the Company has approved capital in the amount of €5,077,799.00 (previous year: T€5,078).

The capital reserves include the premium from the issue of shares. There has been no change in this reserve since the previous period. In accordance with Austrian regulatory requirements, this reserve can only be used to cover eventual losses.

NON-CURRENT LIABILITIES

The Company has no liabilities with a residual redemption period longer than five years.

(8) LIABILITIES DUE TO BANKS

The following analysis sets forth non-current bank loans according to currency and interest rates:

In T€	31.03.2006	30.09.2005	Interest rate
Loans linked to research promotion grants	2,633	2,633	3.63% - 5.50%
Loans linked to ERP grants	5,050	1,300	4%
Other bank loans	8,934	8,934	2.40% - 3.80%
Total	16,617	12,867	

The loans outstanding as of 31 March 2006 are, *inter alia*, secured by a guarantee provided by the Sanochemia Ltd., Malta, and by a pledge on the buildings on non-owned land (Neufeld an der Leitha) in the maximum amount of T€ 1,453.

(9) **DEFERRED INCOME**

Deferred income in an amount of T€ 4,363 (PY: T€ 5,739) reflect a prepayment for galantamine deliveries in the period up to 30.9.2009.

CURRENT LIABILITIES

(10) **LOANS DUE TO BANKS**

The following overview shows the non-current financial liabilities due to banks in terms of currencies and interest rates:

in T€	31.03.2006	30.09.2005	Interest rate
Bank loans and overdrafts	422	752	6% - 7%
Bank loans and overdrafts	1,552	1,090	3.39% - 5.50%
ERP promotion loans	0	216	4%
Research promotion loans	0	1,400	3.63% - 5.5%
Total	<u>1,974</u>	<u>3,458</u>	

The liabilities due to banks listed above are secured by guarantees and pledges provided by Sanochemia Ltd., Malta.

(11) **LIABILITIES DUE TO AFFILIATED COMPANIES**

in T€	31.03.2006	30.09.2005
Sanochemia Diagnostics Int., Neuss	106	106
Medinger GmbH, Vienna	191	0
Total	<u>297</u>	<u>106</u>

IV. OTHER INFORMATION

RESEARCH AND DEVELOPMENT

<u>in T€</u>	<u>10/2005-03/2006</u>	<u>10/2004-03/2005</u>
Cost of materials	39	14
Personnel expenses	534	490
Depreciation of tangible assets and amortisation of intangible assets	44	67
Other operating expenses	2,239	1,441
Total	<u>2,856</u>	<u>2,012</u>

CASH FLOW STATEMENT

The cash flow statements are prepared according to IAS 7 and show changes in “cash and cash equivalents” in the course of the quarter.

SEGMENT REPORTING

The Company operates in the following business areas:

- **Human Pharmaceuticals** covers all pharmaceutical activities with the main focus being on the area of imaging with contrast agents for x-ray, CT and in-vitro diagnostics. These products are marketed and sold partly through subsidiaries (Sanochemia Diagnostics) and through cooperation agreements with selected marketing partners.
- **Production** encompasses synthesis (synthetic galantamine, contract synthesis, internal requirements) and pharmaceutical production. This also includes research and development expenditure and income relevant to production.
- **Research and Development** concentrates on identifying and advancing substances for the treatment of central nervous system disorders and on the innovative further development of tried-and-tested substances. This segment is largely responsible for the Company's own research and development activities. Only minimal externally-generated revenues have as yet obtained through contract R&D activities.
- **Reconciliation** is a segment created to record all income, expenses, assets and liabilities which cannot be directly allocated to the segments listed above.

Cost accounting between the segments is calculated using the market rates and conditions applicable to transactions with third parties.

DIVISIONAL RESULTS

<i>in T€</i>	Human Pharmaceuticals		Production		R&D		Reconciliation		TOTAL	
	01.10.05 – 31.03.06	01.10.04 – 31.03.05	01.10.05 – 31.03.06	01.10.04 – 31.03.05	01.10.05 – 31.03.06	01.10.04 – 31.03.05	01.10.05 – 31.03.06	01.10.04 – 31.03.05	01.10.05 – 31.03.06	01.10.04 – 31.03.05
<i>Sales revenue – ext.</i>	6,039	5,665	7,879	9,487	2,452	2	0	9	16,370	15,163
<i>Sales revenue – int.</i>	12	12	2,951	1,881	0	0	-2,963	-1,893	0	0
Total sales revenue	6,051	5,677	10,830	11,368	2,452	2	-2,963	-1,884	16,370	15,163
Operating performance	6,704	6,212	10,160	12,651	3,941	1,099	-3,345	-2,317	17,460	17,645
Operating result	512	341	1,979	4,351	1,086	-913	-1,904	-1,548	1,673	2,231
<i>Investment</i>	202	55	777	648	1,242	1,030	189	186	2,410	1,128
<i>Depreciation & amortisation</i>	408	452	1,195	1,291	44	67	295	158	1,942	1,968
Segment assets	13,470	14,831	30,294	38,113	11,388	7,288	41,806	27,479	96,958	87,711
Segment liabilities	907	582	8,552	812	1,348	258	25,273	28,240	36,080	29,892

FINANCIAL INSTRUMENTS

Derivative financial instruments

During the quarters 10/2005 – 03/2006, the Company invested in derivative financial instruments in the form of forward exchange contracts through the agency of Amafin Asset Management und Finance S.A., Zug, Switzerland – as it had in previous financial periods. Amafin Asset Management und Finance S.A. is an independent asset management company. In accordance with the terms and conditions of Bank Leu for handling option and futures contracts, the bank concludes options and futures contracts on behalf of Sanochemia albeit it in its own name. These transactions involve Sanochemia as the writer of both put and call options. The option premium received through option sales are deposited in a term account.

In accordance with IAS 39, financial instruments are recorded at their market value (without deduction of any transaction costs which would be incurred) on the balance sheet date.

The risks attached to foreign currency transactions lie in the purchase of one currency against another. The leverage on the contractual volume assigned to Amafin Asset Management und Finance S.A. is limited to the five-fold amount of the sum invested by Sanochemia. Amafin Asset Management und Finance S.A. uses a stop loss in the event of an adverse exchange rate trend amounting to 5% of the capital plus premium received. This effectively limits the risks involved.

Interest rate, foreign exchange and credit risks

There has been no significant change in the risks mentioned above since 30.09.2005. The investment criteria applied by Amafin Asset Management und Finance S.A., Zug, for investing in foreign exchange options and forward exchange contracts have not changed since 30.09.2005 resulting in the associated currency exchange risks also remaining unchanged..

	31.03.2006	30.09.2005
	T€	T€
Foreign exchange options		
Other receivables arising out of foreign exchange options	2,848	1,062
Other liabilities arising out of foreign exchange options	5,395	3,069

The foreign exchange options and forward exchange contracts have had the following impact on the company's financial position for the period 1 October 2005 to 31 March 2006:

	T€
Foreign exchange options	
Expenditure arising out of foreign exchange options	-2,775
Income arising out of foreign exchange options	3,778

Forward exchange contracts

Loss	0
Gain	15

EVENTS AFTER THE BALANCE SHEET DATE

No reportable events have occurred since the balance sheet date.

Vienna, 5 May 2006

The Board of Management:



Herbert Frantsits



Anton Dallos



Dr. Josef Böckmann



Maximilian Hudl